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Cone snails (Conus sp.) are poisonous animals that can be found in all oceans where they
developed a venomous strategy to prey or to defend. The venom of these species contains
an undeniable source of unique and potent pharmacologically active compounds. Their
peptide compounds, called conotoxins, are not only interesting for the development of
new pharmaceutical ligands, but they are also useful for studying their broad spectrum of
targets. One conotoxin family in particular, the a-conotoxins, acts on nicotinic acetylcho-
line receptors (nAChRs) which dysfunctions play important roles in pathologies such as
epilepsy, myasthenic syndromes, schizophrenia, Parkinson's disease and Alzheimer's
disease.
Here we define a new subclass of the a-conotoxin family. We purified the venom of a yet
unexplored cone snail species, i.e. Conus australis, and we isolated a 16-amino acid peptide
named a-conotoxin AusIA. The peptide has the typical a-conotoxin CC-Xm-C-Xn-C
framework, but both loops (m/n) contain 5 amino acids, which has never been described
before. Using conventional electrophysiology we investigated the response of synthetically
made globular (IeIII, IIeIV) and ribbon (IeIV, IIeIII) AusIA to different nicotinic acetyl-
choline receptors. The a7 nAChR was the only receptor found to be blocked with a similar
potency by both peptide-configurations. This suggests that both a5/5 conotoxin isomers
might be present in the venom gland of C. australis. NMR spectroscopy showed that no
secondary structures define the peptides' three-dimensional topology. Moreover, the rib-
bon configuration, which is generally considered to be non-native, is more stable than the
globular isomer. Accordingly, our findings show relevancy concerning the a-conotoxin
classification which might be helpful in the design of novel therapeutic compounds.
© 2014 Elsevier Ltd. All rights reserved.1. Introductionn.be, eline_lebbe@Venoms from cone snails (genus Conus) offer a unique
and extensive source of chemical diversity as they are
driven by evolutionary pressure to improve prey capture
and/or protection of the species. These snails are
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sophisticated peptide chemistry and neuropharmacology
by producing a structural and functional variety of neuro-
toxins. Therefore, the Conus venom gland is recognized as
an emerging source of peptide-based therapeutics (Lewis
et al., 2012). Their ability to use a diverse array of small
disulfide-bridged peptides, called conopeptides or con-
otoxins, makes them very unique (Fry et al., 2009). Up to
date, only 0.1% out of potentially 500,000 venom compo-
nents has been functionally and structurally investigated.
The largest group of characterized Conus sp. peptides is the
family of a-conotoxins (belonging to the A-superfamily),
that are selective antagonists of the muscle and neuronal
subtype nicotinic acetylcholine receptors (nAChRs)
(McIntosh et al., 1999). They act at the nAChR acetylcholine
binding site as competitive antagonists and are among the
smallest of the conopeptides (12-20 amino acid residues)
(McIntosh et al., 1999; Terlau and Olivera, 2004). Alpha-
conotoxins have a characteristic CC-Xm-C-Xn-C framework
and these four cysteines can yield three possible disulfide
connectivities: globular (IeIII, IIeIV), ribbon (I-eIV, IIeIII)
and beads (IeII, IIIeIV). However, naturally appearing a-
conotoxins typically exhibit the globular conformation
(Janes, 2005). The number of residues included within the
two loops (m,n) of a-conotoxins is the basis for the division
into several structural subgroups (m/n: 3/5, 3/6, 4/2, 4/3, 4/
4, 4/5, 4/6, 4/7, 4/8, 5/2 and 5/8) (Akondi et al., 2014). The
most commonly reported framework is the 4/7 subgroup
(Terlau and Olivera, 2004).
Nicotinic acetylcholine receptors, being a member of
ligand-gated cationic channels, mediate fast synaptic
transmission. They are broadly distributed throughout the
peripheral and central nervous systems of both primitive
and evolutionarily advanced organisms (Gotti and
Clementi, 2004). Consequently, nAChR dysfunctions are
involved in a number of central nervous system (CNS)
disorders such as epilepsy, Alzheimer's disease, Parkinson's
disease, schizophrenia, nicotine addiction, pain, cancer etc.
(Albuquerque et al., 2009; Hurst et al., 2013; Improgo et al.,
2010; Tapper et al., 2004).
In mammals there are 16 different nAChR subunits: 9 a-
subunits (a1e7, a9 and a10), 4 b-subunits (b1e4), as well as g,
d and ε subunits. Five of these subunits combine to form
muscle nAChR subtypes (a1b1gd and a1b1dε) which are
found exclusively at neuromuscular junctions, whereas the
other subunits (a2-a10, b2-b4) assemble in numerous
homomeric (exclusively a-subunits) or heteromeric (a- and
b-subunits) neuronal nAChR subtypes (Albuquerque et al.,
2009). The assembly of different pentamers forms a com-
plex variety of nAChR subtypes with different pharmaco-
logical and biophysical properties (Grishin et al., 2010;
Hurst et al., 2013; Indurthi et al., 2014).
Here we report the isolation of a novel 16-amino acid a-
conotoxin from the venom of the vermivorous marine snail
Conus australis and its electrophysiological screening
against six different nAChRs. To the best of our knowledge
this is the first conotoxin to be characterized from this
species found in the Indian Ocean near Tamil Nadu, India.
The peptide, called AusIA belongs to a new subclass of the
a-conotoxin family (i.e. a5/5) which has never been
described before. We investigated the effect of globular(IeIII, IIeIV) and ribbon (IeIV, IIeIII) AusIA on different
nAChRs fromwhich a7 nAChR was the only receptor found
to be blocked with a similar potency by both peptide-
configurations. NMR spectroscopy shows that no second-
ary structures define the peptides' three-dimensional to-
pology. Moreover, the ribbon configuration, which is
considered to be non-native, is more stable than the glob-
ular isomer.
2. Materials and methods
2.1. Cone snail specimens and venom extraction
Specimens of C. australis (identified by Holten in 1802
and classified by Tucker and Tenorio (Tucker and Tenorio,
2009)) were collected from the Indian Ocean near Tamil
Nadu, India. The venomous apparatuses (venom bulbs and
venom ducts) were extracted from the specimens as pre-
viously described (Olivera et al., 1985). The collected tissue
was preserved in RNAlater solution (Ambion) and stored at
20 C. The venomous apparatuses were used for peptide/
protein extraction with 50% acetonitrile (ACN)/water.
2.2. Peptide fractionation and purification
Sample fractionation occurred by reversed-phase high
performance liquid chromatography (RP-HPLC, Gilson,
Middleton, WI, USA). Two steps were followed for the sep-
aration of the venom compounds. In the first step, the
lyophilized crude venom powder was solubilized into 50%
acetonitrile (ACN)/water and aliquots were loaded on a Gel
filtration Superdex™ Peptide 10/300 GL column with 50%
ACN/water as mobile phase (flow rate 0.5 ml/min) to sepa-
rate the peptides and proteins based on their size. Three
sample collectionsweremade thatwere stored overnight at
80 C, freeze-dried and finally solubilized in 0.1% tri-
fluoroacetic acid (TFA)/H2O. For the second step, an
analytical Vydac C18 column (218MS54, 4.6 250mm, 5-mm
particle size; Grace, Deerfield, IL) with a two solvent system
was used: (A) 0.1% trifluoroacetic acid (TFA)/H2O and (B)
0.085% TFA/ACN. The sample was eluted at a constant flow
rate of 1 ml/min with a 0e80% gradient of solvent B over
90 min (1% ACN per minute after 10 min of solvent A). The
HPLC column elutes were monitored by a UV/VIS-155 de-
tector (Gilson) scanning both 214 nm and 280 nm.
2.3. Peptide sequencing
Isolated AusIA was collected and freeze-dried for direct
peptide sequencing and molecular mass analysis (MALDI-
TOF). A Protein Sequencer PPSQ-31A/33A (Shimadzu,
Japan) was used to determine the amino acid sequence of
the separated compound. In this Edman degradation
method, the sample was loaded onto a polybrene-
pretreated, precycled glass fibre disk, and was Edman
sequenced for 24 residue cycles.
2.4. Peptide synthesis and folding
AusIA(g) (globular) and AusIA(r) (ribbon) were synthe-
sized by GenicBio Limited (Shanghai, China). Formation of
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selective protection and deprotection strategy in vitro. The
resulting bicyclic peptides were subsequently purified by
HPLC and analysed with LC-MS (Waters ZQ2000, USA),
then freeze-dried and stored at 20 C until use. Prior to
functional characterization, the purity of the synthetic
peptides was checked and a chromatographical character-
ization was undertaken by RP-HPLC. On the basis hereof, a
careful comparison of the retention time with the one of
the native material was done. Thematerial needed for NMR
spectroscopy was purified using RP-HPLC.2.5. Functional characterization
Complementary DNA encoding the nAChR-channels
was subcloned into the corresponding vector: human a3/
pcDNA3(XbaI), human a4/pGEM-HE(NheI), chick a7/
pBlueScript(NotI), human b2/pSP64(PvuII), human b4/
pcDNA3(XbaI), rat a1/pSP0oD(SalI), rat b1/pSP0oD(SalI), rat
g/pSP0oD(SalI), rat d/pSP0oD(SalI), rat ε/pSP0oD(SalI). The
linearized plasmids - respective restriction enzymes are
indicated in parentheses - were transcribed using the T7
(a3, a4, a7, b4) or the SP6 (b2, a1, b1, g, d, ε) mMESSAGE-
mMACHINE transcription kit (Ambion, Austin, TX).
The harvesting of stage V-VI oocytes from anaesthetized
female Xenopus laevis frogs was previously described (Van
Der Haegen et al., 2011). Oocytes were injected with
50e70 nl of cRNA at a concentration of 1e3 ng/nl using a
micro-injector (Drummond Scientific, Broomall, PA). The
oocytes were incubated in a ND96 solution containing:
96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2 and
5 mM HEPES (pH 7.4), supplemented with 1.25 ml/l
gentamicin and 90 mg/l theophylline. Oocytes were stored
for 1e5 days at 16 C until sufficient expression of nAChRs
was achieved.
Whole-cell currents from oocytes were recorded at
room temperature (18e22 C) by the two-electrode
voltage clamp technique using a GeneClamp 500 ampli-
fier (Molecular Devices, Sunnyvale, CA, USA) controlled by
a pClamp data acquisition system (Molecular Devices,
Sunnyvale, CA, USA). Oocytes were placed in a bath con-
taining ND96 solution. Voltage and current electrodes
were filled with 3 M KCl, and the resistances of both
electrodes were between 0.5 and 1.5 MU. The elicited
currents were sampled at 100 Hz and filtered at 50 Hz
using a four-pole, low pass Bessel filter. To eliminate the
effect of the voltage drop across the bath grounding
electrode, the bath potential was actively controlled by a
two-electrode bath clamp. During recordings, oocytes
were continuously perfused with ND96 at a rate of 2 ml/
min, with the conopeptides applied during 30 s before
ACh was added. ACh (200 mM for a7, 70 mM for a3b4, 50 mM
for a4b2 and a4b4, 10 mM for a1b1gd and a1b1dε) was
applied for 2 s at 2 ml/min, with 30 s washout periods
between different ACh applications and 200 s after toxin
application. The percentage response or percentage inhi-
bition was obtained by averaging the peak amplitude of at
least three control responses (two directly before exposure
to the peptide and one after 200 s washout). The synthetic
peptides were dissolved in ND96 according to the desiredconcentrations. These peptide concentrations were
controlled using spectrophotometry.
Whole-cell current traces were evoked from a holding
potential of 90 mV. Concentration-response curves were
constructed by application of different toxin concentrations
to the nAChR-expressing oocytes. The percentage of
nAChR-blockade was plotted against the logarithm of the
applied concentrations and fitted with the Hill equation:
y ¼ 100/[1 þ (IC50/[toxin])h], where y is the amplitude of
the toxin-induced effect, IC50 is the toxin concentration at
half maximal efficacy, [toxin] is the toxin concentration and
h is the Hill coefficient.
Comparison of two sample means was made using a
paired Student's t test (p < 0.05). All data are presented as
mean ± standard error (S.E.M) of at least 3 independent
experiments (n  3). All data was analysed using pClamp
Clampfit 10.0 (Molecular Devices®, Downingtown, PA) and
Origin 7.5 software (Originlab®, Northampton, MA).2.6. NMR spectroscopy
Initially temperature (5e30 C) and pH (3.8e6.0)
dependent 1D proton spectra were recorded for both pu-
rified peptide samples (AusIA(g) and AusIA(r)), with
2e3 mM peptide solution (200 mL) in H2O:D2O on a
500 MHz (equipped with a 5 mm TCI HCP Z-gradient
probe) and 600 MHz (equipped with a 5 mm TCI HCN Z-
gradient cryoprobe) Bruker Avance II NMR spectrometer.
Detailed two-dimensional (2D) NMR spectra for AusIA(r)
were recorded with a 3 mM solution (200 mL, pH 4.0) of the
folded peptide in H2O:D2O (9:1) mixture at 5 C on
600 MHz NMR spectrometer. All spectra were processed by
using Topspin 2.1 (Bruker Biospin) and analysed with the
program CARA (version 1.8.4) (Keller, 2004).
In the 1D and 2D spectra the water signal was sup-
pressed by using excitation sculpting with gradients
(Hwang and Shaka, 1995). Two-dimensional NOESY spectra
(mixing time 200 and 300ms) were recorded with a sweep
width of 7210 Hz in both dimensions, 64 scans, 2048 data
points in t2, and 1024 free induction decays (FIDs) in t1.
Two-dimensional total correlation spectroscopy (2D-
TOCSY) (Shaka et al., 1988) in 90% H2O was recorded with
DIPSI2 sequence for mixing (mixing time 80 ms). A double
quantum-filtered correlation spectrum (DQF-COSY)
(Derome and Williamson, 1990) in H2O was acquired using
excitation sculpting with gradients for water suppression
with a sweep width of 7210 Hz in both dimensions, 64
scans, 2048 data points in t2, and 1024 FIDs in t1. In the
processing of two-dimensional spectra, data were apo-
dized with a shifted sine-bell square function in both
dimensions.
Natural abundance 1H, 13C heteronuclear single quan-
tum correlation (1He13C HSQC) spectrum was recorded
with sensitivity enhancement and gradient coherence se-
lection, optimized for selection of aliphatic CH groups
(JCH ¼ 135 Hz) using 64 scans, 1024/2048 complex data
points, and 12072/7210 Hz spectral widths in t1 and t2
respectively. For the selection of aromatic CH groups 170 Hz
was used for JCH along with 64 scans, and 128/2048 com-
plex data points.
E.K.M. Lebbe et al. / Toxicon 91 (2014) 145e1541483. Results
3.1. Isolation of a novel a-conotoxin in C. australis venom
N-terminal Edman degradation of the purified active
peptide revealed a novel 16-residue a-conotoxin, called
AusIA, with the sequence SCCARNPACRHNHPCV and a
molecular mass of 1763.90 Da, determined by MALDI-TOF
(4800 Analyzer, Applied Biosystems, USA). This is in per-
fect agreement with the mass of the synthetic peptide
(1764.03 Da) which has been determined by LC-MS and the
theoretically calculated mass of 1764.03 Da (online Peptide
Mass Calculator-Peptide Protein Research Ltd.). To the best
of our knowledge, AusIA is the first conotoxin isolated and
pharmacologically characterized from C. australis, a worm
hunting cone snail species commonly found in the Indian
Ocean in Tamil Nadu, India. The RP-HPLC purification of C.
australis venom is shown in Fig. 1. The fraction containing
AusIA is indicated with and arrow (see Fig. 1). Remarkably,
AusIA has 5 amino acids in both m and n loops. This clas-
sifies the peptide as an a5/5 conotoxin which, to the best of
our knowledge, has never been described before.
3.2. Alpha-conotoxin AusIA isomers
Typically, a-conotoxins have a globular configuration
(CysIeCysIII; CysIIeCysIV). Therefore this configuration is
assumed to be the native one (Janes, 2005). We decided to
investigate both globular (IeIII, IIeIV) and ribbon (IeIV,
IIeIII) isomers of AusIA, which we named a-conotoxinsFig. 1. C18 reversed phase HPLC profile of the third gel filtration fraction of C. aust
AusIA.AusIA(g) and AusIA(r) respectively. The potency and
selectivity of both isomers at neuronal and muscle subtype
nAChRs was determined by examining its effect on ACh-
evoked currents mediated by different nAChR subunit
combinations expressed in Xenopus oocytes. Both peptides,
AusIA(g) and AusIA(r) (10 mM), only inhibited ACh-evoked
current amplitude mediated by a7 nAChRs (40% and 51%
respectively; Figs. 2 and 3). No remarkable effect was seen
at the muscle subtype nAChRs a1b1gd and a1b1dε as well as
at neuronal subtype nAChRs a3b4, a4b2, and a4b4 (Figs. 2
and 3). Concentration-response curves for AusIA(g) and
AusIA(r) inhibition of ACh-evoked currents at the a7 nAChR
revealed an IC50 value of 11.68 ± 1.53 mM and
9.67 ± 0.01 mM respectively. Hill coefficients were 1.85 and
5.20 for AusIA(g) and AusIA(r) respectively (Fig. 4).
3.3. NMR spectroscopy
In order to investigate the structural properties of
AusIA(g) and AusIA(r), we carried out solution state NMR.
The proton NMR spectra of the first peptide, AusIA(g),
appeared severely broad in the tested screening conditions
(Fig. 5A). These broad spectra indicate that at least two or
more conformers of AusIA(g) exist in an intermediate rate
of exchange. It is therefore unlikely that AusIA(g) has any
uniquely folded structure and consequently, no detailed
NMR investigation could be performed.
In contrast, the spectra of AusIA(r) were more prom-
ising. In lower pH, one set of major NMR signals appeared
(Fig. 5B) together with a minor form (Fig. 6). Detailed two-ralis venom. The arrow indicates the peptide described in this work, namely
Fig. 2. Electrophysiological profile of AusIA(g). During recordings, oocytes were continuously perfused with ND96 at a rate of 2 ml/min, with 10 mM AusIA(g)
applied during 30 s before ACh was added. ACh (200 mM for a7, 70 mM for a3b4, 50 mM for a4b2 and a4b4, 10 mM for a1b1gd and a1b1dε) was applied for 2 s at 2 ml/
min, with 30 s washout periods between different ACh applications and 200 s after toxin application.
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AusIA(r) at pH 4.0. This was done following the standard
procedures as outlined by Wüthrich and co-workers
(Wuthrich, 1986).Fig. 3. Electrophysiological profile of AusIA(r). During recordings, oocytes were c
applied during 30 s before ACh was added. ACh (200 mM for a7, 70 mM for a3b4, 50 mM
min, with 30 s washout periods between different ACh applications and 200 s afteThe coupling constant (3JHNHa) values of AusIA(r) are
indicated in Fig. 5B. All values are between 5 and 9 Hz
which indicates that the angle averages across the Phi di-
hedrals and points to some flexibility in the peptideontinuously perfused with ND96 at a rate of 2 ml/min, with 10 mM AusIA(r)
for a4b2 and a4b4, 10 mM for a1b1gd and a1b1dε) was applied for 2 s at 2 ml/
r toxin application.
Fig. 4. Concentrationeresponse curve on a7 nAChR. Different concentration of AusIA(g) (,, A), AusIA(r) (B, B) were tested on a7 nAChRs. The corresponding
IC50 values are 11.68 ± 1.53 mM and 9.67 ± 0.01 mM respectively. Currents were obtained as described under “Materials and Methods”. The percentage of block was
plotted against the logarithm of the tested concentrations. The results were fit with the Hill equation and the Hill coefficients were 1.85 and 5.20 for AusIA(g) and
AusIA(r) respectively.
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show coupling values around 6 Hz, which can be an indi-
cation of an equilibrium between a helix and a coil for-
mation. For the backbone amide protons, the temperature
shift coefficients show an average value of 4.2 ppb/K (Dd/
DT) per residue (Fig. 7) [lit. values for shielded and exposed
residues are <3 ppb/K and >5 ppb/K respectively
(Raghothama, 2010)]. Interestingly, amino acid residues
between Ala4 and His13 have temperature shift coefficients
mostly 3 ppb/K. This may indicate the existence of a
quasi-stable helical region in the middle of the peptide,
since these amide protons are not highly exposed to the
water molecules in the solvent. However, the absence ofFig. 5. Proton NMR spectra of AusIA(g) (A) and AusIA(r) (B) demonstrating structur
dimensional spectrum, recorded at 5 C is shown at higher pH (in blue) and lower p
residue labels and the corresponding 3JHNHa coupling (Hz) values are provided on t
legend, the reader is referred to the web version of this article.)any medium range NOE confirms that AusIA(r) is devoid of
any stable secondary structural unit such as a-helices or b-
turns. This is in contrast with most other 3D structures of
the a-conotoxin family (Chi et al., 2004; Park et al., 2001).
4. Discussion
a-Conotoxins are defined as a family of cysteine-rich
peptides having the typical CC-C-C framework and acting
as competitive antagonists of nicotinic acetylcholine re-
ceptors (Dutertre and Lewis, 2006). In general, there are
two different nAChR subtypes: neuronal and muscle. The
neuronal a7 nAChRs have been investigated thoroughlyal flexibility in the solution state. Backbone amide proton region of the one-
H (in red). Amide proton signals of AusIA(r) at pH 4.0 are labelled with their
op of the peaks. (For interpretation of the references to colour in this figure
Fig. 6. Overlay of the “fingerprint” region of TOCSY (in blue) and DQF-COSY
(in red and pink) spectra of AusIA(r). Cross-peaks arising from the major
form and the exchange peaks from the minor form are marked with their
corresponding residue numbers without and with a prime (0), respectively.
(For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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important functions in the brain, including regions
involved in learning and memory, the hippocampus and
the cerebral cortex (Breese et al., 1997; Rubboli et al., 1994;
Wevers et al., 1994). Consequently, a7 nAChR dysfunctions
are associated with a variety of severe pathologies such as
certain types of epilepsy, myasthenic syndromes, schizo-
phrenia, Parkinson's and Alzheimer's diseases (Gotti and
Clementi, 2004; Lebbe et al., 2014b; Sacco et al., 2004;
Steinlein and Bertrand, 2010).
As mentioned earlier, the number of residues included
within the two loops (m/n) of a-conotoxins is the basis forFig. 7. Chemical shift (d in ppm) vs. temperature (K) plot for the backbone
amide proton of different residues of AusIA(r). Temperature shift coefficients
(Dd/DT in ppb/K) are mentioned within parentheses beside the residue
labels.the division into several structural subgroups (m/n: 3/5, 3/
6, 4/2 4/3, 4/4, 4/5, 4/6, 4/7, 4/8, 5/2 and 5/8) (Akondi et al.,
2014; Lebbe et al., 2014b). The loop size is believed to
roughly correlate with the pharmacological target selec-
tivity. In general, a-conotoxins with a 3/5 framework are
isolated from fish-hunting snails and are mainly active to-
ward fish and/or mammalian neuromuscular nAChRs,
whereas conotoxins from the 4/3, 4/4, 4/5, 4/6 or 4/7 classes
primarily interact with mammalian neuronal nAChRs
(Terlau and Olivera, 2004). Exceptions do exist, since there
are also 4/7 and 4/4 conotoxins that affect the muscular
nAChR subtypes. The pharmacophore of these neuronal
nAChR targeting a-conotoxins has been investigated in
detail. It is composed of a conserved hydrophobic patch in
the first loop which determines binding, and a more vari-
able second loop, which administers selectivity through
pairwise interactions with different nAChRs subunits
(Dutertre et al., 2005). In this study, we revealed the amino
acid composition from a new a5/5 conotoxin from C. aus-
tralis, called AusIA, of which both loops (m/n) consist of 5
amino acids. This is exceptional since, as far as we are
aware, no such peptide has been described. The first loop of
AusIA, having two Ala amino acids, is more hydrophobic
than the second loop which contains following hydrophilic
amino acids: one Arg, two His and one Asn. Moreover,
AusIA has a Pro at position 7 which is conserved among all
a-conotoxins. As is visualized in Fig. 8, also amino acids Ala8
and Pro14 of AusIA are regularly found in other a-con-
otoxins. AusIA shows the highest percentage of similarity
(67%) with Pu1.3, an a4/5 conotoxin of Conus pulicarius, a
worm-hunting cone snail species as well (Yuan et al., 2007).
Other a-conotoxins showing a moderate percentage ofFig. 8. Alignment of 16 a-conotoxins with AusIA, sorted by percentage of
identity (indicated in the left column) with AusIA. References from top to
bottom: AnIB (C. anemone, (Loughnan et al., 2004)), GIC (C. geographus,
(McIntosh et al., 2002)), MII (C. magus, (Cartier et al., 1996)), PnIA (C. pen-
naceus, (Luo et al., 1999)), TxIA (C. textile, (Dutertre et al., 2007)), Vc1.1 (C.
victoriae, (Sandall et al., 2003)), EpI (C. episcopates, (Loughnan et al., 1998)),
ArIA (C. arenatus, (Whiteaker et al., 2007)), OmIA (C. omaria, (Talley et al.,
2006)), TxIB (C. textile, (Luo et al., 2013a)), RegIIA (C. regius, (Franco et al.,
2012), Lp1.10 (C. leopardus, (Yuan et al., 2007)), PuSG1.2 (C. pulicarius,
(Kaas et al., 2012)), PeIA (C. pergrandis, (McIntosh et al., 2005)), Lo1a (C.
longurionis, (Lebbe et al., 2014b)), Qc1.5 (C. quercinus, (Yuan et al., 2007)),
Pu1.3 (C. pulicarius, (Yuan et al., 2007)), AusIA (C. australis, this work).
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(Yuan et al., 2007), Lo1a (61%; Conus longurionis) (Lebbe
et al., 2014a) and PeIA (56%; Conus pergrandis) (McIntosh
et al., 2005). The activity of Qc1.5 has not yet been deter-
mined while Lo1a targets mainly a7 nAChRs and PeIA tar-
gets a9a10, a3b2, a3b4, a6/a3b2b3 and a6/a3b4 nAChRs. It
appears that Arg5 and the C-terminal Val16 of AusIA are
rarely observed in other a-conotoxins at these particular
positions.
In this study we investigated both globular (IeIII, IIeIV)
and ribbon (IeIV, IIeIII) AusIA isomers. Once the activity of
AusIAwas determined electrophysiologically, we employed
NMR-based techniques to elucidate the structure of this
novel peptide. The NMR data revealed that both peptides,
AusIA(g) and AusIA(r), adopt very flexible structures
without having a unique folded structure, lacking any sta-
ble a-helical and/or b-turn units. While AusIA(g) appears to
exist in an intermediate rate of exchange between at least
two conformers, AusIA(r) shows to have a major conformer
(Fig. 6).
These results are remarkable in several points of view.
First, the similar IC50 values (11.68 ± 1.53 mM and
9.67 ± 0.01 mM for AusIA(g) and AusIA(r) respectively) cite
to a similarity in potency. This demonstrates that the Cys-
connectivity is less important for the peptides' potency.
The most important value is arguably the basis structure
having a typical hydrophobic patch determining binding,
which has been demonstrated before (Chi et al., 2004;
Dutertre et al., 2005; Luo et al., 2013a, 2013b)). Previous
work of Khoo et al. (2012) showed that both peptide iso-
mers of m-conotoxin KIIIA (-CC-C-C-CC-) are functional
peptides, raising questions about which, if either, is the
‘native’ disulfide pattern in the venom of Conus kinoshitai
(Khoo et al., 2012). Other work by Safavi-Hemami et al.
(2012) provided evidence of the presence of both globular
and ribbon forms of a-conotoxin ImI in the venom of Conus
imperialis (Safavi-Hemami et al., 2012). Additionally, non-
native disulfide isomers have also been reported for other
a-conotoxins such as GI (Conus geographus) and AuIB
(Conus aulicus) (Dutton et al., 2002; Gehrmann et al., 1998).
Therefore, onemight believe that here too both isomers are
present in the venom gland of C. australis. However, chro-
matographically we could not demonstrate this unequivo-
cally because the RP-HPLC retention times are almost
identical for both synthetically synthesized isomers (data
not shown). Secondly, from both peptides the ribbon iso-
mer is slightly more potent, but significantly more stable in
solution than the globular isomer. The higher potency of
the ribbon isomer has been described for one other a-
conotoxin only, namely AuIB (C. aulicus) which selectively
blocks the a3b4 nAChR subtype (Luo et al., 1998).
In an attempt to correlate the structureefunction rela-
tionship, it appears that other a-conotoxins such as Lo1a of
the a4/7 conotoxin family, form a robust folded structure,
and consequently show higher affinity binding and inhi-
bition of the receptor (Lo1a has an IC50 value of
3.24 ± 0.70 mM on a7 nAChRs) (Lebbe et al., 2014a). Being
not structured, both peptides, AusIA(g) and AusIA(r),
demonstrate weak inhibition compared to that of Lo1a for
the same receptor. Onemight speculate that the ‘real’ target
is another receptor or ion channel, or else, that differentcombinations of a or b nAChR subunits might lead to a
variation in potency. In this context, a-conotoxin Vc1.1 is an
interesting example. Synthetic Vc1.1 (ACV1) was initially
shown to potently block neuronal (a3, a5, a7 and b4 nAChR
subunits) versus muscle nAChRs (Livett et al., 2006).
Therefore it was selected for testing in pain models
revealing Vc1.1 as the first a-conotoxin exhibiting efficacy
in these models (Sandall et al., 2003; Satkunanathan et al.,
2005). Later, Vincler et al. showed that Vc1.1 is a potent
antagonist of a9a10 nAChRs which potentially contributes
to its analgesic effect (Vincler et al., 2006).
Another explanation might be the impaired affinity-
selectivity of a5/5 conotoxins, possibly providing an
answer for their rare biological existence. It is also tanta-
lizing to speculate that the superior family of toxins like a4/
7 and others with well-defined structureefunction prop-
erties may have been evolved and the rare a5/5 family
became extinct in some Conus species. Finally, further
characterization is needed in order to know if AusIA can
displace a-bungarotoxin from a7 nAChRs, and as such to see
if an overlapping binding site is shared or not. Moreover
this would indicate whether or not AusIA shows affinity for
the AChBP.
In summary, we defined a new subclass of the a-con-
otoxin family. We isolated an a5/5 conotoxin, called AusIA,
from the venom of C. australis, from which both globular
and ribbon isomers demonstrated a similar potency on a7
nAChRs. Therefore, our study broadens the a-conotoxin
subfamily classification which might be useful regarding
the design of novel (therapeutic) compounds.Acknowledgements
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